Profound Medical to Participate in the Stifel 2025 Healthcare Conference

Rhea-AI Summary

Profound Medical (NASDAQ:PROF) will present an update at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 1:20 p.m. ET in New York City. Management's presentation will be broadcast live and later archived on the company's investor website under News & Events.

The company describes itself as a commercial-stage medical device maker of customizable, AI-powered, incision-free therapies for tissue ablation.

News Market Reaction – PROF

-2.51%

1 alert

-2.51% News Effect

On the day this news was published, PROF declined 2.51%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 1:20 p.m. Eastern Time in NYC.

The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "News & Events" in the Investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO^®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. The TULSA Procedure is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with the TULSA Procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

FAQ

When will Profound Medical (PROF) present at the Stifel 2025 Healthcare Conference?

Profound will present on November 11, 2025 at 1:20 p.m. Eastern Time in New York City.

How can investors watch Profound Medical's (PROF) Stifel 2025 presentation?

The presentation will be broadcast live and later archived on the company's investor website under News & Events.

What topics will Profound Medical (PROF) cover at the November 11, 2025 presentation?

Management will provide an update on the company's business; no specific financials or new product data were announced in the notice.

Where is the archived webcast of Profound Medical's (PROF) Stifel 2025 talk posted?

The archived webcast will be posted at www.profoundmedical.com in the Investors section under News & Events.

Will Profound Medical (PROF) present financial guidance at the Stifel 2025 Healthcare Conference?

The announcement states management will present a business update but does not mention any specific guidance or financial disclosures.

Which stock symbol should investors search for when looking up Profound Medical ahead of the November 11, 2025 presentation?

Use the Nasdaq ticker PROF (also listed as TSX:PRN) when researching the company before the presentation.